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Treatment of patients with immunosuppressive drugs after
solid organ transplantation (SOT) is a delicate balance between
under-immunosuppression which may result in rejection and over-
immunosuppression may result in severe opportunistic infections [1].
To date, no idealmarker exists that reliably reveals the status of immune
function in SOT recipients [1]. Torque-Teno virus or Transfusion-
transmitted virus (TTV) is a virus that has gained attention as a possible
marker of immune function [2–5]. TTV is found in water, air, soil and
also in human body samples. TTV rarely causes disease in healthy indi-
viduals, and TTV viral load in immunosuppressed patients is higher than
in healthy controls [6].
In this systematic review,we describe the role andpotential function
of TTV viral load as a marker of immune function and hence level of im-
munosuppression in SOT recipients.
2. Description of the virus
TTV is a non-enveloped, circular single strand DNA virus first identi-
fied in a patient with acute post-transfusion hepatitis in 1977 [7]. TTV is
a member of the Anellovirus family characterized by the presence of a
circular DNA [8]. This virus is 30–50 nm in diameter, and the genome
is 3.8 kb in length and contains 3739 base pairs (bp) expressing 3 mes-
senger RNAs (mRNAs) [9]. These mRNAs use alternative start codons
(AUGs) for translation and encode at least 6 open reading frame (ORF)
proteins [9]. To date, 29 genotypes of TTV have been discovered and
classified in 5 genogroups [10]. It is estimated that N3.8 × 1010 copies/
ml of TTV virions are generated in the healthy human body per day
and that N90% of these are cleared by the immune system. Conse-
quently, in cases with detectable viral load, TTV viral load remains
about 102 to 108 copies/ml [11].
2.1. Protein synthesis and immunobiology of TTV
In the genome of TTV, ORF1 is the longest encoded region with
the highest rate of genetic mutations [12]. This gene encodes a
capsid protein (ORF1 protein) that may help TTV in immune eva-
sion and persistence [13]. The ORF2 genome region encodes the
ORF2 protein that can inhibit NF-kappa-B translocation from cyto-
sol to nucleus and as a result interrupt translation of genes and
decrease production of inflammatory cytokines and enzymes
such as interleukin (IL)-6, IL-8 and cyclooxygenase 2 [8,14]. The
ORF3 region in genotype 1 encodes the ORF3 protein that mayhave a role in cell cycle and antiviral resistance [12,13]. Moreover,
TTV-derived apoptosis-inducing protein (TAIP) is a protein
encoded by the ORF3 region in TTV genotype 1 that induces apo-
ptosis in hepatocellular carcinoma (HCC) cells [15].
All TTV proteins are antigenic and generate an antibody response,
though the intensity of this response varies [13]. Anti-TTV IgM begins
to increase 10–21weeks after TTV infection and 5–11weeks later it usu-
ally decreases and finally disappears. Anti-TTV IgG starts to increase
about 16 weeks after infection and can be detected for at least 4 years.
Despite detectable antibody titers, anti-TTV antibodies are neither pro-
tective nor neutralizing [11].
On antigen-presenting cells (APCs) such as B-lymphocytes, mono-
cytes/macrophages and plasmacytoid dendritic cells, toll-like receptor
(TLR)-9 recognizes TTVDNA as a foreignDNA and depending on the po-
sition and number of cytosine-phosphate-guanine (CpGs) motifs, this
trigger or inhibits production of inflammatory cytokines [8,16]. Further-
more, TTVproducesmicroRNAs (miRNAs) that inhibit interferon signal-
ing, improve TTV evasion, and facilitate TTV persistence in the host
[17,18].
TTV viral load increases under conditions with compromised im-
mune response [4]. Replication of TTV is inversely correlated with
number and especially functions of T-lymphocytes [3,19,20]. In addi-
tion to iatrogenic or drug induced immunosuppression, some genetic
variations or polymorphisms in the co-stimulatory molecule cytotoxic
T-lymphocyte antigen 4 (CTLA-4) or CD152 may affect TTV replication
after hematopoietic stem cell transplantation (HSCT) [21]. CTLA-4 is
an inhibitory receptor that is expressed on the surface of activated
T-cells. This receptor acts as a negative regulator of T-cell mediated
immune response [21]. Polymorphisms in CTLA-4 may result in stron-
ger inhibition of T-cell proliferation and activation and therefore a
more intensified suppression of immune response to TTV [21]. TTV
replication in different tissues, especially in hepatic cells, can induce
production of pro-inflammatory cytokines such as interferon-gamma
(IFN-γ), tumor necrosis factor-alpha (TNF-α) and Chemokine (C\\C
motif) ligand 7 (CCL7) [22]. CCL7 is a chemo-attractant for different
subtypes of leukocytes that may contribute to the pathology of inflam-
matory diseases and cancers [22,23]. Furthermore, some studies indi-
cate that TTV can trigger autoimmune diseases such as multiple
sclerosis (MS) with antigenic mimicry or by suppression of regulatory
T-cells (Tregs) [24–26]. Recently, it was suggested that TTV may play a
role in immunosenescence as TTV viral load higher than 4.0 log cop-
ies/ml is a strong predictor of mortality in elderly subjects [27]. How-
ever, defining the exact mechanism of this correlation requires further
investigations [27].
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TTV is transmitted by parenteral, trans-placental, by breast milk, re-
spiratory and fecal-oral routes [28,29]. TTV can be found inmost tissues
and cells except red blood cells and platelets [12,29]. TTV is polytrophic
and replicates in liver, bonemarrow and peripheral bloodmononuclear
cells, especially T lymphocytes [29,30]. Although one recently published
study has suggested that granulocytes are the primary site for TTV rep-
lication after HSCT in children [31]. Because of the presence of lympho-
cytes, TTV viral load is 100 times higher in whole blood than in plasma
[32]. Accordingly, TTV can be detected by quantitative or qualitative po-
lymerase chain reaction (PCR) techniques in different clinical specimens
[33–36]. Furthermore, immunoassays including enzyme immunoassay
(EIA) and enzyme-linked immunosorbent assay (ELISA) are used to de-
tect antibodies against ORF1 (anti-N22 polypeptide) or ORF2 proteins
[37,38].
Up to now, there is no widely standardized TTV diagnostic method.
PCR is an accurate method, however, applying different primers results
in variable diagnostic sensitivity. Moreover, PCR is relatively expensive,
requires advanced laboratory instruments and expert technicians limit-
ing the analysis to resource strong centers [29,38]. Recently, a standard-
ized quantitative real time PCR for detection of TTV (TTV R-GENE®
assay) was introduced by a group of researchers in France [39]. Limit
of detection of this assay in blood and plasma samples is 146 copies/
ml (2.16 log10 copies/ml) and 167 copies/ml (2.22 log10 copies/ml), re-
spectively. This assay can detect 12 human TTV genotypes and is com-
patible with different thermo-cyclers. Furthermore, the assay has been
tested in healthy volunteers, donors and kidney transplant recipients
and the diagnostic accuracy has been confirmed [39]. Other detection
methods such as EIA and ELISA are cheaper and easily performed, but
these methods have limited use since they detect antibodies, and they
cannot differentiate between current and previous infections due to
the large overlap in time between IgM and IgG antibodies [38].
2.3. Pathogenicity factors
Contrary to what was initially assumed, TTV is not necessarily a
pathogen, and it may be considered a part of the human virome
[5,12]. Pathogenicity may be genotype dependent. Thus, TTV genotype
1 has been found both in healthy carriers and in patients with elevated
liver enzymes and hepatitis with unknown etiology [12,40]. TTV geno-
type 4 is not prevalent in healthy subjects, but it has been found in pa-
tients with inflammatory conditions such as rheumatoid arthritis and
severe acute respiratory diseases [16]. The TTV viral load is higher in
drug induced immunosuppressed patients compared to healthy carriers
[6,41,42]. Furthermore, TTV viral load is higher in patients co-infected
with other microorganisms such as Epstein Barr Virus (EBV) [24],
Human PapillomaVirus (HPV) [43], Helicobacter pylori [44], human im-
munodeficiency virus (HIV) [45] and Cytomegalovirus (CMV) infection
[46] compared to TTVmono-infected patients. Age and gender are other
factors that have been associated with TTV viral load with the highest
viral loads found in older men and the lowest found in young women
[46]. Importantly, TTV viral load increases in patients with autoimmune
or inflammatory diseases and in immunocompromised patients
[25,47–50].
2.4. Prevalence of detectable TTV replication
TTV is ubiquitous and the prevalence of detectable TTV replication is
about 12% in drinkingwater, 15% in hospital setting air and surface sam-
ples, and 38–100% in wastewater samples [29].
In humans, the prevalence of detectable TTV replication ranges from
0 to 48% in samples from cord blood or blood samples from newborns
depending on the PCR technique applied. This prevalence increases dur-
ing the first months after birth and reaches up to 67% in 1 to 12months
old healthy infants [35]. Breastmilk is oneof the important transmissionroutes, and TTV is detected in 23 to 67% of breast milk samples [35].
Furthermore, fecal-oral is another rout of transmission and TTV DNA is
detected in 84% of saliva [51] and 25% of fecal samples [52] fromhealthy
individuals.
The prevalence of detectable TTV replication varies in different
geographical regions and populations, and TTV has in some regions
been detected in as many as 95% of healthy individuals [12,53]. It
should be noted that measuring prevalence of detectable TTV replica-
tion is highly dependent on the assays applied, so cross-study com-
parisons should be avoided [35,54–56]. Factors such as type of
specimen (for example plasma or whole blood) and different PCR
methods or primers can affect the prevalence of detectable TTV rep-
lication [32,35,54,55]. For example, the reported prevalence of pa-
tients with detectable TTV DNA in kidney transplant recipients by
nested PCR is about 33% using primers specific for ORF1 region
while it is 92% among the same patients when using primers specific
for non-coding region of the TTV genome [54].
Here we will systematically review and describe the role and poten-
tial function of TTV as an endogenous marker of immune function and
hence level of immune suppression in SOT recipients.3. Methods
We searched PubMed and Scopus (up to 2018 Dec 31) using
this keywords combination: (“TTV” OR “Torquetenovirus” OR
“Alphatorquevirus”) AND (“Transplant*” OR “reject*” OR “infect*”
OR “immune*”) and found 185 articles.
We excluded studies that did not refer to SOT, case reports, reviews,
duplicates and papers in languages other than English (155 papers
excluded).
We included 30 articles including original articles, short reports,
commentaries (letter to editor) and conference proceedings that ap-
peared to contain information relevant to the TTV and SOT.
We define the type of studies and level of evidence for each article
according to guidelines of Oxford center for evidence-based medicine
(CEBM) (https://www.cebm.net). This grading system has 5 levels.
Studies in level 1 contain the strongest and studies in level 5 include
the weakest evidences [57].4. Results and discussion
4.1. Solid organ transplantation
In all SOT recipients immunosuppressive therapy is initiated before
or at the time of transplantation in order to prevent rejection and in-
crease organ and patient survival [58–60]. Usually, a multidrug regimen
containing agents with different mechanism of action is used for induc-
tion or maintenance of immunosuppression and high-dose steroids or
combination of immunosuppressive agents is used for treatment of re-
jection [59,60]. In the following, five main groups of immunosuppres-
sive agents are described, and their mechanism of action is presented
in supplementary table 1.
Biological agents are antibodies and due to intense and rapid ac-
tion, these agents are often used for induction of immunosuppression
[59]. Calcineurin inhibitors (CNI) such as Tacrolimus and Cyclospor-
ine are the second group of immunosuppressants and the corner-
stone of immunosuppressive therapy [59]. It should be noted that,
as their target molecules differ, Tacrolimus is more potent than Cy-
closporine in calcineurin inhibition [59]. The third group includes
anti-proliferative agents such as Azathioprine and mycophenolic
acid based agents. Mammalian targets of rapamycin (mTOR) inhibi-
tors such as Sirolimus and its derivative Everolimus are a fourth
group of immunosuppressants [58]. Finally, the last group is Cortico-
steroids such as Prednisolone [58,59].
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4.2.1. Prevalence and associated factors
Studies including data on TTV in kidney transplant recipients are
presented in supplementary table 2. In kidney transplant recipients,
prevalence of patients with detectable TTV DNA has been estimated to
range between 10 and 100% (supplementary table 2) [55,56,61,62].
The prevalence of various TTV genotypes in kidney transplant recipients
differs in different geographical areas, i.e. genotypes 2 and 5 are the
most prevalent genotypes in Brazilian kidney transplant recipients
[61] while genotype 1 is the most common genotype in Hungary [56].
In recent studies, it has been suggested that age and gender are asso-
ciated with TTV in kidney transplant recipients [2,63,64]. TTV viral load
is higher in older and male recipients and may also be higher in recipi-
ents with older donors [63,64], though data are inconsistent [54,56,65].
4.2.2. TTV viral load during the course of transplantation
TTV viral load increases rapidly from day 7 to day 30 and peaks
aroundmonth 3 to 12 post-transplantation [2,64], and the viral load de-
creases gradually after this time [2,63].
4.2.3. Association with immunosuppressive drugs
TTV mostly replicates in T-lymphocytes and administration of T-cell
depleting agents such as Anti-Thymocyte globulins (ATG) results in TTV
viral load decrease on day 7 of therapy with a rebound after day 15 [3].
ATG results in a larger TTV viral load reduction than Basiliximab that in-
hibits proliferation and activation of T-cells [3,59],while the highest TTV
viral load has been found in patients on belatacept-based immunosup-
pression [63]. Belatacept blocks co-stimulation of T-cells and inhibits
generation of antiviral T-cells that may leads to insufficient suppression
of TTV replication [59,63]. In contrary with short-term, inmid-term and
during post-transplant months 1 and 3, there are negative correlations
between TTV viral load and number of CD3+, CD4+ and CD8+ T lym-
phocytes [2]. Partial repopulation of T-cells, differences in ATGdosage or
concurrent prescription of other immunosuppressive agents in different
studies and induction of immunosenescence by ATG may explain this
discrepancy [2].
The serum levels of CNI do not correlate with TTV viral load during
the first months after kidney transplantation [3,63,64]. However, the
TTV viral load is higher in patients on regimens containing tacrolimus
compared to regimens containing cyclosporine or mTOR inhibitors
[63]. In addition, TTV viral load is higher in patients that receive high
doses (N1.5 g) of Mycophenolic acid compared to patients receiving
lower doses [64].
4.2.4. Association with infection and rejection
CMV-seropositive recipients have higher TTV viral load than sero-
negative patients [2,66]. Thismay represent the impact of CMV infection
on induction of immunosenescence and accordingly control of TTV rep-
lication by the immune system in transplant recipients [2]. TTV viral
load is higher in recipients with primary CMV infection post transplan-
tation compared to patients with latent or reactivation of CMV infection
(positive CMV IgG before transplantation). However, CMV prophylaxis
has no effect on TTV viral load [64]. In a study including 280 SOT recip-
ients (146 kidney, 134 liver recipients), 235 (145 kidney, 90 liver recip-
ients) had CMV reactivation. Interestingly, among these SOT recipients,
TTV viral load higher than 3.45 log DNA copies/ml 10 days post-
transplant was an independent predictor of subsequent CMV reactiva-
tion with sensitivity and specificity of 83.1% and 56.2%, respectively
[66]. In kidney transplant recipientswithout a clinical diagnosis of BK vi-
remia, Anelloviridae subtypes (including TTV) are the dominant viral
family. However, in kidney transplant recipients, with a clinical diagno-
sis of BK viremia the polyomaviridae are the dominant viral family [67].
Antibody-mediated rejection (ABMR) is one of the major causes of
graft loss in kidney transplant recipients and associated with inade-
quate immunosuppression [63]. In a recent study, including 715 (669ABMR negative & 46 ABMR positive) kidney transplant recipients, it
was demonstrated that higher TTV viral loadwas independently associ-
ated with lower ABMR risk. The risk of ABMR decreases by 0.91 with
each log increase in TTV viral load [63]. Based on this finding it has
been suggested that TTV viral load reflects the efficiency of immunosup-
pression in this group of kidney transplant recipients [63]. In agreement
with this finding, higher pre-transplant TTV viral load is associatedwith
lower rate of acute graft rejection [2].
4.3. Liver or pancreas transplantation
4.3.1. Prevalence and associated factors
Summary of studies including data on TTV in liver transplant recipi-
ents is presented in supplementary table 3. TTV has been reported to be
prevalent (16–100%) in liver transplant recipients. The genogroups 2
and 5 are more prevalent among liver transplant recipients than
among healthy controls, but no TTV genogroup has been reported to
be particularly predominant in liver transplant recipients [6,41]. There
exists no information about prevalence of detectable TTV replication
in pancreas transplant recipients [3].
Neither age and sex, nor post-transplant time, number of blood
transfusions and reason for transplantation are associated with TTV
viral load in liver transplant recipients [6,68].
4.3.2. TTV viral load during the course of transplantation
In liver transplant recipients, TTV viral load progressively increases
and peaks three months post transplantation [4,41,66,69,70]. Hereafter,
the viral load starts to decline during the 6–12month post transplanta-
tion [4,70] to reach a baseline level on average N12 years post transplan-
tation [70].
4.3.3. Association with immunosuppressive drugs
Intensity of immunosuppression is associated with TTV viral load
[4,70]. Patients that receive CNI plus azathioprine or mycophenolate
mofetil have higher TTV viral loads than patients on CNI alone
3 months post transplantation [41]. The type of CNI (Tacrolimus vs.
Cyclosporine) does not influence TTV viral load in liver transplant recip-
ients [41,70].
4.3.4. Association with infection and rejection
In liver transplant recipients, hepatitis B virus (HBV) and hepatitis C
virus (HCV) co-infection are not associated with an increased TTV viral
load [41]. However, TTV viral load is lower in hepatitis E virus (HEV)
co-infected (anti-HEV IgM and IgG positive) pediatric liver transplant
recipients compared to HEV negative recipients [6]. Moreover, despite
TTV viral load not being associated with HCV co-infection, HCV treat-
mentmay affect TTV viral load as this decreases in liver transplant recip-
ients with recurrent HCV infection, when treated with pegylated
interferon and ribavirin [41]. In contrast, the TTV viral load is higher
during episodes of CMV infection (defined as CMV DNA N1000 copies/
ml) compared to infection free time points [70]. In addition, as men-
tioned earlier TTV viral loadhigher than3.45 logDNAcopies/ml predicts
subsequent CMV infection with high sensitivity and specificity [66]. In
liver transplant recipients with post-transplant renal impairment, de-
tectable TTV viral load in serum is higher in recipients without BK
viruria than recipients with BK viruria. It is likely that TTV and BK
virus replicate in the same urothelial cells and competitively use the
same cellular factors, and/or BK virus suppress the replication of TTV
virus [71].
From an immunological perspective, it is notable that the incidence
of biopsy-proven acute cellular rejection (ACR) in the first post-
transplantation year is lower in liver transplant recipients that are
TTV-positive than in TTV-negative at the time of transplantation (21%
vs. 70%, P= .004) [68]. Effects of confounding factors such as age, gen-
der, concomitant viral infections and number of immunosuppressive
agents have been evaluated in a proportional regression model that
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ing the first year after transplantation [68]. Moreover, TTV viral load is
lower in patients with clinical episodes of ACR with the lowest TTV
viral loads detected in patients with moderate ACR compare to mild or
non-ACR patients [70]. TTV viral load with a cut-off of 4.75 log10 cop-
ies/ml has been demonstrated to predict ACR (especially in moderate
ACR) with sensitivity, specificity, and negative and positive predictive
values of, 100%, 77%, 100% and 38%, respectively [70]. TTV viral load be-
fore liver transplantation or during first week and first month post
transplantation cannot predict upcoming ACR accurately [70]. Thus,
measuring TTV viral load before or during the first week after liver
transplant has not been found to be an accurate predictor of infection
or rejection [70].
4.4. Lung and/or Heart transplantation
4.4.1. Prevalence and associated factors
Summary of studies including data on TTV in lung and/or heart
transplant recipients is presented in supplementary table 4. Information
about prevalence of detectable TTV replication in heart transplant recip-
ients is limited [72]. The reported prevalence of detectable TTV replica-
tion in heart transplant recipients ranges from25 to 79%, and genogroup
2 is present in 40% of heart transplant recipients [72].
Lung transplant recipients are a group of SOT recipients with high
prevalence of detectable TTV replication (up to 95%) [20]. The most
prevalent genotype has not been identified [20,73–77]. However, a re-
cent study has found that TTV strains of genogroup 3 aremore prevalent
in BAL and blood samples of lung transplant recipients compared to
healthy controls [78].
The TTV viral load has been measured in blood samples and
broncho-alveolar lavage (BAL) fluid specimens from both lung donors
and recipients. Surprisingly, the TTV viral load is found to be higher in
BAL fluid from donors than healthy volunteer controls. TTV viral load
is inversely correlated with age, while no correlation to history of to-
bacco exposure, aspiration and cause of death is found [75]. Neurohu-
moral and inflammatory responses, lung infiltration with leukocytes
and iatrogenic immunosuppression by corticosteroids in brain-dead
lung donors are possible reasons for higher TTV viral load in the patients
[75], but more studies are needed to determine the exact etiologic
factors.
The BAL fluid TTV viral load in lung transplant recipients is not cor-
related with transfusion of blood products, type of transplant (single
or double lung) or cause of preoperative lung disease [75].
4.4.2. TTV viral load during the course of transplantation
In lung transplant recipients, TTVDNA is detectable in BALfluid from
the first hour after lung re-perfusion [75]. In blood samples, the TTV
viral load increases during the first 3 months after transplantation
[20,73,77] with an incremental trend starting 15 days after initiation
of immunosuppressive drugs peaking about day 60 after transplanta-
tion [20] and reaching a steady state 120 days after transplantation
[79]. The TTV doubling time does not seem to be associated with age,
gender or underlying disease [20]. In children, TTV viral load is associ-
ated with race and age and is higher in non-Caucasians and older lung
recipients compared to Caucasians and younger recipients [80].
4.4.3. Association with immunosuppressive drugs
As noted above, the TTV viral load is associated with intensity of im-
munosuppression in SOT recipients [4,41]. Because of the more intensi-
fied immunosuppressive regimens in lung transplant recipients, the
TTV viral load reaches higher levels compared to other SOT recipients
[73]. It is controversial if there is correlation between TTV viral load
and CNI serum levels. Previous studies describe that TTV viral load cor-
relates with Tacrolimus and Cyclosporine serum levels [73,77], and the
TTV viral load is lower in patients on Cyclosporine containing regimen
6–24 month post transplantation [73,77]. However, a recent studycould not find any association between CNI serum level and TTV viral
load [79].
4.4.4. Association with infection and rejection
Some studies have investigated the association between TTV viral
load and the risk of infections in lung transplant recipients [73,77,79].
One study reported that the TTV viral load is higher in lung transplant
recipients 28 to 76 days before diagnosis of an infection. The authors
concluded that plasma TTV viral load higher than 9.3 log10 copies/ml
after 90days of transplantation could beused to predict the risk of infec-
tion with a sensitivity and specificity of about 53% and 91%, respectively
[73]. In line with this study, a recent study demonstrated that an upper
threshold of 9.2 log10 copies/ml and a lower threshold of 8.1 log10 cop-
ies/ml predicted infectious events with a sensitivity and specificity
of 87% and 71%, respectively [81]. These results, however, was
contradicted by a study concluding that the mean TTV viral load was
not associated with and cannot predict infections [77]. It should be
noted that in the first and second study, Tacrolimus (74% and 100%)
was the predominantly used CNI, while Cyclosporine was used in 80%
of cases in the third study [73,77,81]. TTV viral load is lower in patients
on Cyclosporine containing regimens [73,77]. Thus, the difference in re-
sults may be due to differences in choice of CNI.
Notably, primary graft dysfunction (PGD) is associated with slower
increase in BAL fluid TTV viral load compared to controls (non PGD
lung transplant recipients) during the peri-transplant period [75]. In pa-
tients with biopsy-proven lung rejection, TTV viral load in serum starts
to decrease by the rate of one log per month [79]. Each one log10 de-
crease in TTV viral load increases the risk of ACR by 2 fold [81]. More-
over, a 10-fold decrease in TTV viral load per month can predict
rejection with sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) of 74%, 99%, 83% and 97%, respec-
tively [79].
Chronic lung allograft dysfunction (CLAD) is a type of rejection that
is associatedwith inadequate immunosuppression. It has been reported
that TTV viral load lower than 7.0 log10 copies/ml can predict the risk of
CLAD indicating that TTV viral load lower than this cut-off is a predictor
of insufficient immunosuppression [76]. Furthermore, each one log10
decrease in TTV viral load increases the risk of CLAD by 40% [81].
Although, TTVmay have limited value to predict immune related events
during thefirst 1–2months post-transplant because its kinetics is differ-
ent among individual patients. Moreover, TTV kinetics is not associated
with clinical parameters and induction regimens in this 1–2months pe-
riod [81].
5. Discussion
Potential role of TTV as marker of immunosuppression or immune
activation in solid organ transplantation.
Several studies found that TTV viral load and kinetics are associated
with immune status i.e. presence of infection or rejection in SOT
[3,4,6,63,68,75–77,82]. However, many studies were of poor quality
with low level of evidence, including small studies without appropriate
control groups. Thus, at present there is not sufficient evidence to sup-
port a role for TTV viral load as an accurate marker of immunosuppres-
sion or infections. At best, the current knowledge may be used to
generate hypotheses regarding the role and usability of TTV.
To clarify the role of TTV viral load as a reliable predictor of the level
of immunosuppression or risk of infections or rejection, a number of is-
sues should be addressed. At first, the measurement technique should
be standardized [79,83,84]. Using a unique and standard method such
as digital droplet PCR (dd-PCR) [77] or TTV R-GENE® assay [39] for
measurement of TTV, may result in a better reproducibility of findings.
One may speculate that the burden of immunosuppression can be
tailored in each recipient by stratification according to detectable TTV
viral load. However, many other factors could interfere. TTV has an af-
finity to T-lymphocytes and administration of anti-T lymphocyte agents
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tion immunosuppressive therapy (for example CNI plus anti-
proliferative agents) has the greatest effects on TTV viral load [41]
which may explain why TTV viral load is higher in SOT recipients with
more intensified immunosuppressive regimens compared to less im-
munosuppressed patients [73]. Although the number of T cells does
not decrease, the ability of T cells to control the virus diminishes [63].
TTV viral load is lower in kidney transplant recipients that receive
mTOR inhibitors comparedwith Tacrolimus [63]. The antiviral potential
of mTOR inhibitors could be one of the explanations for this observation
[85]. In addition to drug induced immunosuppression, attention should
also be paid to genetic variations or polymorphisms of immune modu-
lating molecules as these variations may affect function of T cells and
hereby change the rate or amount of TTV replication in transplant recip-
ients [21]. Thus, future studies should focus on the impact of different
types of immunosuppressive agents and preferentially include healthy
controls. Such studies should focus at establishing possible associations
between TTV and immune functions using deep immunological profil-
ing including functional immunological assays.
There is sparse evidence to suggest that TTV is a predictor of infec-
tions and rejections. Most of the available studies are cross-sectional
or retrospective studies and/or do not have relevant controls. In case
of prospective studies or cohorts, most of previous studies are single
center studies with limited number of patients. Thus, detectable TTV
replication at the time of transplantation and increases in TTV viral
load in the peri-transplant period may be associated with lower acute
cellular rejection [68] and lower risk of PGD [75]. Moreover, higher
TTV viral load is correlated with lower risk of ABMR [63] and TTV viral
load with a specific cut off can predict upcoming infections [73] and
the risk of CLAD [76]. These associations suggest that TTV viral load
may be useful as a predictive marker for immunosuppression or im-
mune activation in solid organ transplantation [76]. However, larger
prospective studies with clinical relevant and well-defined endpoints
are warranted. TTV seroprevalence is not 100% and this may introduce
bias we cannot account for. Some factors can influence TTV seropreva-
lence including, sensitivity of assay, time since exposure to TTV, lack of
exposure and cross-reactivity with other antibodies. However, in this
paper we have reported TTV prevalence according to detectable TTV
replication and not according to serology tests (Seroprevalence). In fu-
ture studies, in parallel to PCR, it could be interesting to investigate
the serology of TTV among donors and recipients before and after trans-
plantation to differentiate TTV reactivation from acute infection as is al-
ready implemented for CMV monitoring [86].
In conclusion, it remains to be shown if TTV is an accurate marker of
level of immune suppression, or if TTV is a predictor of complications
such as infections or rejections. To do this, we need larger prospective
cohort studies with well-defined end-points that compare different im-
munosuppressive regimens. Although more research is needed, the use
of the TTV viral load could be an interesting tool as an add-on to the cur-
rent strategies to monitor immune status and immune-related compli-
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